DECLARE-TIMI 58

The trial, DECLARE-TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events) is a multi-national, randomized, double-blind, placebo-controlled Phase IIIB trial jointly led by the TIMI Study Group and Hadassah Medical Center, and sponsored by AstraZeneca and Bristol-Myers Squibb. DECLARE – TIMI 58 is a superiority trial and designed to test the hypothesis that in patients with type 2 diabetes mellitus long-term treatment with dapagliflozin, an oral sodium glucose cotransporter 2 (SGLT2) inhibitor, will reduce one or both of the co-primary endpoints: (1) the incidence cardiovascular death, myocardial infarction, or ischemic stroke or (2) the incidence of cardiovascular death or hospitalization for heart failure. The trial will also seek to definitively exclude unacceptable cardiovascular risk from dapagliflozin in these patients. It has randomized approximately 17,150 patients with type 2 diabetes mellitus and either known cardiovascular disease (secondary prevention cohort) or at least two risk factors for cardiovascular disease (primary prevention cohort). DECLARE-TIMI 58 is an event-driven trial, and we estimate that subjects will be followed for a median of 4.5.

LINK TO CLINICALTRIALS.GOV

TRIAL SITE LOG-IN